SIG SAUER Announces U.S. Army Designates Type Classification Milestone for the NGSW Lethality Program
NGSW Type Classified
NEWINGTON, N.H., May 21, 2025 /PRNewswire/ -- SIG SAUER, industry leading manufacturer of elite military weapon systems, is proud to congratulate the U.S. Army on the milestone of officially designating Type Classification - Standard (TC-STD) to the SIG SAUER Next Generation Squad Weapon (NGSW) M7 rifle and M250 (belt fed) automatic rifle— cornerstone systems of the U.S. Army's modernization program and overmatch efforts. The M7 is the M4 carbine replacement, and the M250 replaces the M249 Squad Automatic Weapon; the systems bring superior range and lethality over legacy systems, providing a greater threat to enemy forces through superior overmatch.
The Type Classification affirms the M7 and M250 meet stringent performance, safety, and reliability standards for widespread military use. This designation ensures seamless integration into the U.S. Army's inventory, streamlining procurement, training, and maintenance across units and asserting the materiel fully satisfies U.S. Army operational needs. This milestone marks the transition of these advanced firearms from developmental to standardized status, signifying readiness for widespread fielding.
"This approval underscores the U.S. Army's commitment to equipping our soldiers with next generation lethality to maintain tactical superiority and enhance mission success," states Steve Rose, Executive Vice President, Defense Strategies Group. "The M7 and M250 represent a transformative leap in combat capability."
The NGSW Program, initiated in 2017, aims to revolutionize small arms capabilities for the U.S. Army. Following a 27-month prototype phase, extensive testing culminated in the selection of SIG SAUER's XM7 and XM250 in April 2022.
About SIG SAUER, Inc.: SIG SAUER, Inc. is a leading provider and manufacturer of firearms, electro-optics, ammunition, airguns, suppressors, remote controlled weapons stations, and training. For over 250 years, SIG SAUER has evolved and thrived by blending American ingenuity, German engineering, and Swiss precision. Today, SIG SAUER is synonymous with industry-leading quality and innovation, which has made it the brand of choice amongst the U.S. Military, the global defense community, law enforcement, competitive shooters, hunters, and responsible citizens. Additionally, SIG SAUER is the premier provider of elite firearms instruction and tactical training at the SIG SAUER Academy. Headquartered in Newington, New Hampshire, SIG SAUER has over 3,400 employees across sixteen U.S. locations in three states, and four additional global facilities. SIG SAUER is certified a Great Place to Work™. For more information about the company and product line visit: sigsauer.com.
Media Contact: Phil Strader Vice President, Consumer Affairs phil.strader@sigsauer.com
SOURCE SIG SAUER, Inc.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight
MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2025 MedTech Innovation Spotlight on Friday, June 13, 2025. Inspire is scheduled to present at 12:00 p.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at About Inspire Medical SystemsInspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit Investor and Media ContactEzgi YagciVice President, Investor Relationsezgiyagci@ in to access your portfolio
Yahoo
22 minutes ago
- Yahoo
EXCLUSIVE: Vivakor Announces Special Stock Dividend
Vivakor, Inc (NASDAQ:VIVK) announced on Friday that its Board of Directors has approved a plan to issue a special dividend to Vivakor shareholders. Vivakor currently holds 206,595 (approximately 13.5% of the outstanding common) shares of Adapti, Inc (OTC:BRZLD), a company that manages the marketing of products, data, and companies through its AdaptAI software platform. Based on Vivakor's current shares outstanding of approximately 47.3 million and excluding 20.96 million shares held by the company's CEO and CFO, who are waiving their right to the dividend, each Vivakor shareholder will be entitled to receive approximately 0.0079 shares of Adapti, Inc common stock per Vivakor share. Also Read: Based on the current share price of Adapti's common stock, the special dividend is worth approximately $0.815 million. Vivakor's Board of Directors will establish a date of record for the dividend in the next couple of weeks. Vivakor reported first-quarter revenue growth of 133% Y/Y to $37.3 million, primarily attributed to the sales of logistics and terminal realized through the operations of our newly acquired Endeavor Entities' businesses. Operating loss for the quarter increased 298% to $(4.8) million. EPS loss of $(0.21), compared to $(0.07) a year ago. Price Action: VIVK stock is up 7.64% at $0.9147 premarket at the last check Friday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article EXCLUSIVE: Vivakor Announces Special Stock Dividend originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) has unveiled promising early results from its Phase 1b trial of ORIC-944, a novel PRC2 inhibitor, in combination with androgen receptor inhibitors for metastatic castration-resistant prostate cancer (mCRPC). The study reported broad and deep prostate-specific antigen (PSA) responses, with a 59% PSA50 response rate (47% confirmed, plus one pending) and a 24% confirmed PSA90 response rate. These robust responses were seen across all dose levels and with both apalutamide and darolutamide combinations. Most patients remain on therapy, with several approaching one year or more of treatment. A scientist examining cells in a lab, representing the company's dedication to developing specialty pharmaceuticals. Safety data were also encouraging: the vast majority of adverse events were mild or moderate (Grade 1 or 2), primarily gastrointestinal, supporting long-term dosing suitability. Only one patient experienced a Grade 3 event, and there were no severe (Grade 4 or 5) treatment-related adverse events. ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) plans to advance two recommended Phase 2 doses for each combination into further study, with a global Phase 3 trial set to begin in the first half of 2026. To support these efforts, ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced a $125 million private placement financing led by top healthcare investors, extending its cash runway into the second half of 2027 and through the anticipated Phase 3 trial readout. While we acknowledge the potential of ORIC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ORIC and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.